Amisulpride: A first-line option in the management of schizophrenia
Drugs and Therapy Perspectives, ISSN: 1172-0360, Vol: 18, Issue: 7, Page: 1-4
2002
- 11Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures11
- Readers11
- 11
Article Description
Amisulpride is an atypical antipsychotic that is specific for dopamine D and D receptors. It is as effective as haloperidol, flupenthixol and risperidone in reducing overall and positive symptoms in patients with acute exacerbations of schizophrenia with predominant positive symptoms. It tended to be more effective than other agents in alleviating negative symptoms and provided better control of affective symptoms. Amisulpride is also effective for long-term maintenance therapy in patients with chronic schizophrenia with positive or mixed positive and negative symptoms. In addition, it improves quality of life and social functioning in patients with chronic schizophrenia when given long term. In common with other atypical agents, amisulpride has less propensity to induce extrapyramidal effects than conventional antipsychotics. Amisulpride has minimal neurocardiac effects and a low potential for drug interactions.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0036062709&origin=inward; http://dx.doi.org/10.2165/00042310-200218070-00001; http://link.springer.com/10.2165/00042310-200218070-00001; https://dx.doi.org/10.2165/00042310-200218070-00001; https://link.springer.com/article/10.2165/00042310-200218070-00001
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know